Lord Mayor Alastair King, Chairman of the British Liver Trust, was delighted to visit the Roger Williams Institute of Liver Studies (RW-ILS). The British Liver Trust organised the visit of the Lord Mayor and Lady Mayoress of the City of London on May 2nd, to recognise the institute’s leadership in liver disease research and care.
Joined by senior representatives from the RW-ILS Board of Trustees, King’s College London, King’s College Hospital NHS Foundation Trust, and the British Liver Trust, Alastair King learned about the urgent challenges in liver research and the Institute’s pioneering work, from basic discovery science, translational research and clinical care to policy influence and public health.
Conversations during the visit centred on the shared objectives of the founding organisations of the RW-ILS, including enhancing outcomes for those affected by liver disease, accelerating research, and the crucial need to train future leaders in liver health.
During his tour of the Institute, the Lord Mayor Alastair King met with clinicians and researchers leading innovative translational initiatives. Professor Debbie Shawcross, attending as both a clinician-researcher and the first female President of the European Association for the Study of the Liver (EASL), highlighted the Institute’s growing global reputation.
Commenting on X (Twitter), the Lord Mayor said: “London is a leading centre for life sciences and health research. We were honoured to have a tour of the recently-launched Roger Williams Institute of Liver Studies at the Denmark Hill campus of King’s College London, of particular interest to me as chair of the British Liver Trust.”
RW-ILS Director, Professor Philip Newsome, said: “King’s is home to one of the world’s most concentrated hubs of liver expertise, making it uniquely positioned to lead progress in this critical field. We were delighted to welcome the Lord Mayor and Lady Mayoress of London to the RW-ILS to share more about how the Institute is bridging the gap between cutting-edge science and real-world patient outcomes, and the future directions of liver research and care.”
